Assure to Attend Investor Conferences in November 2020
DENVER, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announced that management will participate in the following investor conferences in November 2020:
- GCFF Virtual Conference November 5, 2020. Assure’s executive chairman and CEO John Farlinger is scheduled to present on November 5th at 1:05 p.m. ET. GCFF is the largest conference catering to the Chinese investment community in North America. For more information and to register for free, please visit: https://gcff-nov-2020-en.eventbrite.ca/?aff=PR.
- Opal Group's Virtual Family Office and Private Wealth Fall Forum November 11-12, 2020. Management will be participating in virtual one-on-one meetings with family offices, high net worth investors and investment advisors.
- Virtual Fall Investor Summit November 16-18, 2020. Assure’s executive chairman and CEO John Farlinger is scheduled to present on November 16th at 2:00 p.m. ET. Management will be participating in virtual one-on-one meetings with institutional investors. Register for the webcast here: https://www.webcaster4.com/Webcast/Page/2038/38399.
- Sidoti’s Virtual Microcap Investor Conference November 19, 2020. Assure’s executive chairman and CEO John Farlinger is scheduled to present on November 19th at 1:00 p.m. ET. Management will be participating in virtual one-on-one meetings with institutional investors. Register for the webcast here: https://sidoti.zoom.us/webinar/register/WN_n52kCa6JTZKlR_86DirQvA.
About Assure Holdings
Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission’s Gold Seal of Approval®. For more information, visit the company’s website at www.assureneuromonitoring.com.
This news release may contain “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and economic activity in general, and risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
Released November 4, 2020